Actinium Pharmaceuticals Inc (ATNM)

May 6, 2025, 8:45 AM EDT - 7 days ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 3, 2025, 8:10 AM EDT - 10 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 30, 2025, 7:25 AM EDT - 13 days ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 28, 2025, 12:27 PM EDT - 15 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

Apr 28, 2025, 8:30 AM EDT - 15 days ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 15 days ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 24, 2025, 5:00 AM EDT - 19 days ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 19, 2025, 8:20 AM EDT - 24 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 17, 2025, 5:45 AM EDT - 26 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 16, 2025, 10:01 AM EDT - 27 days ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Mar 28, 2025, 11:57 AM EDT - 6 weeks ago

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)

Mar 27, 2025, 8:45 AM EDT - 6 weeks ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Mar 25, 2025, 6:00 AM EDT - 7 weeks ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Mar 24, 2025, 4:15 PM EDT - 7 weeks ago

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Mar 20, 2025, 8:00 AM EDT - 7 weeks ago

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Mar 19, 2025, 8:30 AM EDT - 7 weeks ago

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Mar 18, 2025, 8:00 AM EDT - 2 months ago

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

Mar 17, 2025, 8:50 AM EDT - 2 months ago

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

Mar 12, 2025, 8:00 AM EDT - 2 months ago

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference

Mar 11, 2025, 8:30 AM EDT - 2 months ago

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

Dec 11, 2024, 9:32 AM EST - 5 months ago

My Top 2 Stock Picks For A 2025 Rebound

AES

Nov 18, 2024, 7:00 PM EST - 6 months ago

SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player

Nov 18, 2024, 8:00 AM EST - 6 months ago

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Nov 4, 2024, 11:00 AM EST - 6 months ago

Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 7:30 AM EST - 6 months ago

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Nov 3, 2024, 11:00 AM EST - 6 months ago

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

Nov 2, 2024, 11:00 AM EDT - 6 months ago

Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Oct 30, 2024, 11:00 AM EDT - 6 months ago

Actinium Pharmaceuticals, Inc. Is Being Investigated For Violations Of Securities Laws And Affected Shareholders Should Contact The Schall Law Firm

Oct 29, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Actinium Pharmaceuticals Inc For Fraud

Oct 28, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Encourages Investors To Join An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud